Prevalence of antiplatelet therapy in patients with diabetes

Cardiovascular Diabetology

Volumn 4, Issue , 2005, Pages

  Miller, Shaun R ^a   MacLean, Charles D ^a,b   Littenberg, Benjamin ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; COHORT ANALYSIS; MIDDLE AGED; RISK; STATISTICAL MODEL;

ADULT; AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; SEX FACTORS;

EID: 29144470464     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-4-18     Document Type: Article

References (36)

1. Moss SE, Klein R, Klein BE: Cause-specific mortality in a population-based study of diabetes. Am J Public Health 1991, 81:1158-1162.
2. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996, 124:136-145.
3. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
4. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAMA 1979, 241:2035-2038.
5. ETDRS I: Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992, 268:1292-1300.
6. Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L: Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002, 346:1800-1806.
7. Harpaz D, Gottlieb S, Graff E, Boyko V, Kishon Y, Behar S: Effects of aspirin treatment on survival in non-insulin-dependent diabetic patients with coronary artery disease. Israeli Bezafibrate Infarction Prevention Study Group. Am J Med 1998, 105:494-499.
8. Nobles-James C, James EA, Sowers JR: Prevention of cardiovascular complications of diabetes mellitus by aspirin. Cardiovasc Drug Rev 2004, 22:215-226.
9. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002, 136:157-160.
10. Hennekens CH, Dyken ML, Fuster V: Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997, 96:2751-2753.
11. ADA: Aspirin therapy in diabetes. American Diabetes Association. Diabetes Care 1997, 20:1772-1773.
12. Rolka DB, Fagot-Campagna A, Narayan KM: Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes Care 2001, 24:197-201.
13. Persell SD, Baker DW: Aspirin use among adults with diabetes: recent trends and emerging sex disparities. Arch Intern Med 2004, 164:2492-2499.
14. Harrington RA, Becker RC, Ezekowitz M, Meade TW, O'Connor CM, Vorchheimer DA, Guyatt GH: Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126:513S-548S.
15. McFarlane SI, Jacober SJ, Winer N, Kaur J, Castro JP, Wui MA, Gliwa A, Von Gizycki H, Sowers JR: Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002, 25:718-723.
16. Stafford RS: Aspirin use is low among United States outpatients with coronary artery disease. Circulation 2000, 101:1097-1101.
17. MacLean CD, Littenberg B, Gagnon MS, Reardon M, Turner PD, Jordan C: The Vermont Diabetes Information System (VDIS): Study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clinical Trials 2004, 1:532-544.
18. ADA: Aspirin Therapy in Diabetes. Diabetes Care 2004, 27:S72-S73.
19. CAPRIE: A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.
20. Tran H, Anand SS: Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004, 292:1867-1874.
21. Mehta SR, Yusuf S: Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention. J Am Coll Cardiol 2003, 41:79S-88S.
22. Antithrombotic_Trialists'_Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
23. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, et al: The evolving diabetes burden in the United States. Ann Intern Med 2004, 140:945-950.
24. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A: Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003, 26:3264-3272.
25. Short D, Frischer M, Bashford J, Ashcroft D: Why are eligible patients not prescribed aspirin in primary care? A qualitative study indicating measures for improvement. BMC Fam Pract 2003, 4:9.
26. Tecce MA, Dasgupta I, Doherty JU: Heart disease in older women. Gender differences affect diagnosis and treatment. Geriatrics 2003, 58:33-39; quiz 40.
27. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352:1293-1304.
28. Diener HC, Ringleb P: Antithrombotic Secondary Prevention After Stroke. Curr Treat Options Cardiovasc Med 2002, 4:429-440.
29. Faulkner LA, Schauffler HH: The effect of health insurance coverage on the appropriate use of recommended clinical preventive services. Am J Prev Med 1997, 13:453-458.
30. Saaddine JB, Engelgau MM, Beckles GL, Gregg EW, Thompson TJ, Narayan KM: A diabetes report card for the United States: quality of care in the 1990s. Ann Intern Med 2002, 136:565-574.
31. Improvement of Cardiac Outcomes in Kaiser Permanente of Ohio. The Permanente Journal 2000, 4.
32. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348:383-393.
33. Faragon JJ, Waite NM, Hobson EH, Seoldo N, VanAmburgh JA, Migden H: Improving aspirin prophylaxis in a primary care diabetic population. Pharmacotherapy 2003, 23:73-79.
34. Haggerty SA, Cerulli J, Zeolla MM, Cottrell JS, Weck MB, Faragon JJ: Community pharmacy Target Intervention Program to improve aspirin use in persons with diabetes. J Am Pharm Assoc (Wash DC) 2005, 45:17-22.
35. Filippi A, Sabatini A, Badioli L, Samani F, Mazzaglia G, Catapano A, Cricelli C: Effects of an automated electronic reminder in changing the antiplatelet drug-prescribing behavior among Italian general practitioners in diabetic patients: an intervention trial. Diabetes Care 2003, 26:1497-1500.
36. Krein SL, Vijan S, Pogach LM, Hogan MM, Kerr EA: Aspirin use and counseling about aspirin among patients with diabetes. Diabetes Care 2002, 25:965-970.